Company profile
NUVATION BIO INC.
NYSE:NUVBBiotechnology: Pharmaceutical Preparations
Drug pipeline (2)
| Asset | Stage | Revenue | Trials | Status |
|---|---|---|---|---|
| IBTROZI | approved | — | 0 | — |
| TALETRECTINIB | phase3 | — | 8 | active |
Revenue is the latest quarter the company reported for that product, from SEC filings; a fourth quarter is the year less nine months when no filing states one. Trial counts are of the product's ingredients, deduplicated by trial, so products sharing an ingredient share trials.
Clinical trials (18)
| NCT ID | Phase | Status | Start | Completion | Sponsor name | Title |
|---|---|---|---|---|---|---|
| NCT02279433 | phase1 | completed | 2014-09-01 | 2019-03-01 | Nuvation Bio Inc. | A First-in-human Study to Evaluate the Safety, Tolerability and Pharmacokinetics of DS-6051b |
| NCT06564324 | phase3 | recruiting | 2024-11-27 | 2029-01-01 | Nuvation Bio Inc. | A Phase III Study Comparing Taletrectinib With Standard Therapy in ROS1 Positive Locally Advanced or Metastatic Non-small Cell Lung Cancer Patients |
| NCT05357820 | phase1 | completed | 2021-07-19 | 2021-12-03 | Nuvation Bio Inc. | A Study of AB-106 in Chinese Healthy Adult Men Evaluated the Effects of Itraconazole and Rifampicin on AB-106 PK |
| NCT04395677 | phase2 | active_not_recruiting | 2020-07-07 | 2024-06-07 | Nuvation Bio Inc. | A Study of AB-106 in Subjects With Advanced NSCLC Harboring ROS1 Fusion Gene |
| NCT05357911 | phase1 | completed | 2021-07-13 | 2021-08-20 | Nuvation Bio Inc. | A Study on the Effect of AB-106 on the Pharmacokinetics of Digoxin |
FDA applications (1)
| Application | Approved | Type | Applicant | Products | ||||
|---|---|---|---|---|---|---|---|---|
| NDA 219713 | 2025-06-11 | NDA | NUVATION BIO INC | |||||
Loading… | ||||||||